Vontobel Asset Management Inc. Grows Holdings in Boston Scientific Corporation (BSX)

Vontobel Asset Management Inc. boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 19.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,651,580 shares of the medical equipment provider’s stock after buying an additional 266,067 shares during the period. Vontobel Asset Management Inc.’s holdings in Boston Scientific were worth $40,945,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Private Trust Co. NA lifted its holdings in Boston Scientific by 14.5% during the 4th quarter. Private Trust Co. NA now owns 54,642 shares of the medical equipment provider’s stock worth $1,354,000 after buying an additional 6,905 shares in the last quarter. DnB Asset Management AS lifted its holdings in Boston Scientific by 13.1% during the 4th quarter. DnB Asset Management AS now owns 151,150 shares of the medical equipment provider’s stock worth $3,747,000 after buying an additional 17,500 shares in the last quarter. QUANTRES ASSET MANAGEMENT Ltd acquired a new stake in Boston Scientific during the 4th quarter worth approximately $647,000. Prudential Financial Inc. lifted its holdings in Boston Scientific by 149.1% during the 3rd quarter. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider’s stock worth $138,928,000 after buying an additional 2,850,630 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its holdings in Boston Scientific by 12.0% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 2,947,432 shares of the medical equipment provider’s stock worth $85,977,000 after buying an additional 314,917 shares in the last quarter. Institutional investors own 90.51% of the company’s stock.

Shares of Boston Scientific Corporation (BSX) traded down $0.48 on Tuesday, hitting $26.98. 10,923,568 shares of the stock were exchanged, compared to its average volume of 11,921,011. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50. The firm has a market cap of $37,190.00, a price-to-earnings ratio of 44.23, a price-to-earnings-growth ratio of 1.97 and a beta of 0.96. Boston Scientific Corporation has a fifty-two week low of $23.29 and a fifty-two week high of $29.93.

Boston Scientific (NYSE:BSX) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.31. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The company’s revenue was up 5.6% on a year-over-year basis. During the same period last year, the firm posted $0.27 EPS. equities research analysts expect that Boston Scientific Corporation will post 1.25 EPS for the current year.

A number of research firms have issued reports on BSX. Needham & Company LLC reiterated a “buy” rating and set a $32.00 target price on shares of Boston Scientific in a report on Tuesday. Barclays restated a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a report on Wednesday, January 10th. Stifel Nicolaus restated a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a report on Monday, September 25th. Evercore ISI began coverage on shares of Boston Scientific in a report on Wednesday, January 3rd. They issued an “in-line” rating and a $27.00 price objective on the stock. Finally, BMO Capital Markets raised their price objective on shares of Boston Scientific from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, October 27th. Two analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $31.00.

In related news, SVP David A. Pierce sold 8,763 shares of the stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $27.74, for a total value of $243,085.62. Following the transaction, the senior vice president now directly owns 24,201 shares of the company’s stock, valued at approximately $671,335.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction on Monday, October 30th. The shares were sold at an average price of $28.42, for a total transaction of $440,510.00. The disclosure for this sale can be found here. Insiders sold a total of 96,585 shares of company stock worth $2,578,197 over the last ninety days. Insiders own 0.74% of the company’s stock.

WARNING: This piece was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://transcriptdaily.com/2018/01/16/vontobel-asset-management-inc-grows-holdings-in-boston-scientific-corporation-bsx.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply